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 Cleft lip and/or palate are the most prevalent congenital craniofacial birth 
defect in humans. While myriad surgical techniques have been described to repair 
orofacial clefts, several complications have been associated with the repair 
techniques. To overcome these complications, a tissue engineering strategy may be 
employed. In particular, we are investigating strategies for regenerating the alveolar 
bone that is often missing as a result of cleft palates. Numerous materials have been 
explored as biomaterials for bone tissue engineering, however there are 
disadvantages to these, including compromised mechanical properties and harmful 
degradation products. To overcome this issue, a novel class of biomaterials has 
been created. These materials are crosslinked networks of monomers of 5-ethyl-5-
(hydroxymethyl)-β,β-dimethyl-1,3-dioxane-2-ethanol diacrylate. The study 
presented here was designed to determine the effects of the material’s formulation 
scheme on several of its physical properties, so as to develop a novel bone tissue 
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Chapter 1: Introduction 
  
There are several types of orofacial clefts, including cleft palate and cleft lip 
with or without cleft palate1. Cleft lip with or without cleft palate is the most 
prevalent congenital craniofacial birth defect in humans and is seen in about 1 in 
700 live births2, 3. In addition, cleft lip and/or cleft palate comprise the second most 
common congenital anomaly after clubfoot4. The incidence of facial clefting varies 
among ethnic groups, with Native American and Asian populations having the 
highest rate at 3.6 per 1000 live births and 2.0 per 1000 live births, respectively. 
People of European ancestry and African populations have the lowest prevalence at 
1.0 per 1000 live births and 0.3 per live births, respectively5, 6. This translates into 
approximately 15,000 newborns with clefts each year, with a total United States 
population with clefts at any one time of 330,0007.  
 In general, about 30% of all clefts are those of the lip, about 20% are 
isolated cleft palates, and the remaining approximately 50% are combination cleft 
lip and palate8. Cleft lip with or without cleft palate is more frequently seen in 
males, whereas isolated cleft palate is twice as common among females6. 
Approximately 70% of cleft lip and/or cleft palate cases are non-syndromic, 
occurring as an isolated condition. The remaining 30% of cases are syndromic and 
are present in association with another disease or disorder9.  
 Individuals with orofacial clefts often require interdisciplinary treatment 
into adulthood. These individuals, along with their families, may experience the 





a variety of psychosocial issues5. A multitude of surgical techniques have been 
described to repair orofacial clefts. The goals of cleft lip and palate surgery are 
directed toward achieving a normal facial appearance, as well as the ability to feed, 
speak, and hear without significantly affecting the facial development of the patient. 
However, several complications have been associated with the repair of cleft palate 
deformities. Patients are often subjected to multiple revision surgeries over their 
lifetime10, 11. Other complications resulting from surgical cleft palate repair include 
wound dehiscence, scarring of the palate, fistula formation, disturbances in facial 
growth, and mandible retrusion. 
 In order to combat these complications, a tissue engineering strategy may be 
employed in the repair of cleft palate. The field of tissue engineering aims to restore 
function to or replace damaged or diseased tissues through the application of 
engineering and biological principals. These principles include the selection and 
manipulation of cells, identification and use of pertinent biological signaling 
molecules, and the design of biomaterials used as scaffold matrices. 
 The biomaterial scaffold must provide a solid framework for cell growth 
allowing cell attachment and migration. Scaffolds for engineering bone, and palates 
in particular, should be osteoconductive, osteoinductive, biocompatible, and 
biodegradable12. Several materials have been explored as biomaterials for bone 
tissue engineering. However, there are disadvantages to these materials, including 
compromised mechanical properties and harmful degradation products. To 
overcome these issues, a novel class of biomaterials has been created. These new 





examined in this study is 5-ethyl-5-(hydroxymethyl)-β,β-dimethyl-1,3-dioxane-2-
ethanol diacrylate (EHD). These monomers, when reacted together, crosslink to 
form a rigid plastic material.    
 The work presented in this study was designed to determine the effects of 
the EHD network formulation parameters on several properties of the networks. By 
optimizing these properties, the most appropriately functioning biomaterial can be 
created for use in a tissue engineering strategy for the repair of cleft palate, and 







Chapter 2: Tissue Engineering Solutions for Cleft Palates 
 
2.1. Functional palate anatomy 
2.1.1. Anatomy 
 The human skull is comprised of 22 separate bones, as well as 20 deciduous 
and 32 permanent teeth. The bony skull is formed from two components – the 
neurocranium and the viscerocranium. The latter includes the bones of the face, 
such as the mandible, maxilla, zygoma, and nasal, as well as the palatal, pharyngeal, 
temporal, and auditory bones13.  
 The mammalian palate consists of two components: the primary and the 
secondary palate (Figure 1).  These structures together form the roof of the mouth 
and the floor of the nose, separating the oral cavity from the nasal cavities and the 
nasopharynx. The palate consists of two distinct regions, the bony and immobile 






Figure 1. The anatomy of a normal palate. Adapted from [37]. 
 
  
The hard palate is formed by the palatine processes of the maxillae and the 
horizontal plates of the palatine bones. The primary palate is a small but significant 
contributor to the hard palate and is located anterior to the incisive foramen.  The 
primary palate has particular relevance in the cleft deformity.  Anteriorly and 
laterally, the hard palate is bounded by the alveolar processes and the gingivae.  
Posteriorly, it is continuous with the soft palate.  
There are no muscles in the hard palate, but it is covered by keratinized oral 
mucosa which is continuous with the periosteum.  There are numerous minor 
salivary glands in its posterior portion. 
The soft palate is the posterior portion of the palate. It is a mobile muscular 





posteroinferiorly to a curved free margin where the uvula is suspended from the 
midline.  Laterally, the soft palate is continuous with the wall of the pharynx and 
the tongue and the by the palatoglossal and palatopharyngeal muscles identified 
externally as the anterior and posterior tonsillar pillars, respectively.  
The soft palate is covered on its nasal and oral surfaces by non-keratinized 
mucosa. Numerous mucous glands are present on both surfaces, and collections of 
lymphoid tissue are found in the submucosa. There are five muscles of the palate 
including the levator veli palatini, the tensor veli palatini, the palatoglossus muscle, 
the palatopharyngeus muscle, and the musculus uvulae.  The soft palate is 
strengthened by the palatine aponeurosis, formed by the expanded tendon of the 
tensor veli palatini muscle. This aponeurosis is attached to the posterior margin of 
the hard palate and the muscles of the soft palate are attached to the palatine 
aponeurosis14, 15.  
 
2.1.2. Development of the palate 
 The entire viscerocranium and part of the neurocranium are formed from the 
neural crest – a pluripotent cell population derived from the lateral ridges of the 
neural plate during the early stages of embryogenesis13, 16. During craniofacial 
development, cranial neural crest cells migrate ventrolaterally as they populate the 
branchial arches. The formation of mesenchymal structures of the head and neck, 






  The human palate, as well as the palates of other mammals, is formed by 
the unification of three elements – the primary palate, the inferior most extension of 
the frontonasal process, and the two lateral maxillary palatal shelves that together 
will form the secondary palate3. The development of the palate starts at about the 
sixth week of gestation and is a multi-step process that involves palatal shelf 
growth, shelf elevation, midline fusion of palatal shelves, and the disappearance of 
the midline epithelial seam2, 16. 
 The primary palate develops from the fusion of medial nasal prominences. 
This consists of the prolabium that forms the philtrum of the upper lip and the 
triangular-shaped premaxilla that houses the four maxillary incisor teeth. This 
segment represents a small but a critical portion of the hard palate.  It is here where 
the failure to fuse during embryogenesis results in the commonly seen cleft lip and 
palate deformity. 
Between the eighth and twelfth weeks of gestation, the development of the 
secondary palate begins with the formation of the palatal shelves from the maxillary 
processes17. The shelves grow through cell replication and matrix deposition18. As 
the palatal shelves grow, the first branchial arch is oriented vertically downwards 
and surrounded by a layer of undifferentiated epithelial cells. Then, the palatal 
shelves elevate from a vertical to a horizontal position about the dorsum of the 
tongue2. The final stage of secondary palate development occurs when the medial 
edge epithelium fuses the palatal shelves with each other to form a midline palatal 





flow across the intact horizontal palate as the medial edge epithelium 
disintegrates17.  
By the ninth week of gestation, the developing palate begins to fuse at the 
nasal surface with the nasal septum, and this process is completed by the twelfth 
week. The hard palate is formed by ossification in the primary palate and the 
anterior portion of the secondary palate, while the soft palate and uvula are formed 
from the posterior portion of the secondary palate4.  
 
2.2. Cleft palates 
2.2.1. Classifications of clefts 
 A cleft palate occurs when the palatal shelves fail to fuse properly. 
Numerous systems have been devised to classify clefts of the lip and palate, 
however, most simply, cleft palates can be categorized as complete or incomplete 
and described further according to which aspect of the palate they involve. In the 
authors’ minds, accurate anatomic description more than classification, leaves less 
to the imagination and serves best to facilitate surgical planning. 
Complete cleft palates involve both the primary and secondary palates in 
which no fusion between the palatal shelves or the primary palate has taken place. 
These types of clefts are usually associated with a cleft lip. Incomplete cleft palates 
can either involve the primary or the secondary palate in isolation or in 
combination, where fusion between the facial processes or palatal shelves has been 





posterior portion of the soft palate (Figure 2a), it may extend through the soft and 
hard palates to the incisive foramen (Figure 2b), or may be limited to the alveolus. 
 Clefts of the secondary palate can be further classified as unilateral or 
bilateral. When only one palatal shelf fuses to the nasal septum, the cleft is 
considered unilateral (Figure 2c), and the cleft defect is confined to one side of the 
midline. When neither palatal shelf fuses with the nasal septum, the cleft is 
classified as bilateral (Figure 2d)19.  
 
Figure 2. (a) A cleft of the soft palate; (b) A cleft of the soft and hard palate; (c) A 
complete unilateral cleft of the lip and palate; (d) A complete bilateral cleft of the palate 
and lip. Adapted from [37]. 
 
 Lastly, the submucous cleft involves the separation of the intrinsic soft 
palate musculature while the overlying soft palatal mucosa remains intact. This 





2.2.2. Causes of clefts 
 Both genetic and environmental factors contribute to the formation of 
orofacial clefts.  Specific gene defects, maternal smoking, fetal hypoxia, and 
teratogenic drugs have all been linked to the typical cleft dysmorphology.   
Clefting of the primary palate occurs when there is failure of the lateral 
nasal and maxillary processes to make contact with the medial nasal process.  
Alterations in the rate of cell proliferation and morphogenetic movements of the 
facial processes are the driving force for normal fusion.  Abnormalities in cell 
signaling as well as alterations in the epithelium and peridermal cells lining these 
processes appear to be involved in the development of the defect20.  
Clefting of the secondary palate may result from a disturbance at any stage 
of palate development. Defective palatal shelf growth can result in a cleft palate. At 
the precise developmental stage when the palatal shelves have completed growing, 
the shelves begin to elevate. This movement occurs quickly, on the scale of minutes 
to hours, and any delay in the elevation of the palatal shelves may result in the 
failure of their fusion2. Cleft palate can also result from a disturbance in the fusion 
or mesenchymal penetration of the palatine shelves6.  
 
2.2.2.1. Implicated Genetic Factors 
 Several studies have been completed to test a number of genes that may be 
linked with cleft palate. The consensus from these studies is that there is not a 
straightforward single gene that is responsible for clefting. In fact, different genes 





predisposing an individual to cleft palate, including msh homeobox homolog-1 
(Msx1), transforming growth factor-β3 (TGF-β3), T-box transcription factor-22 gene 
(TBX22), poliovirus receptor like-1 (PVRL1), interferon regulatory factor-6 (IRF6), 
and patched (PTCH). The effects of the Msx family of proteins and TGF-β3 in 
relation to cleft palate formation have mainly been studied in mice, but the 
conclusions can be applied to humans. There have been studies about the effects of 
TBX22, PVRL1, and IRF6 in humans.  
 
2.2.2.1.1. Msh homeobox homolog-1 
 The Msx family of proteins is an important modulator of craniofacial, limb, 
and nervous system development. It has been estimated that Msx1 mutations may 
contribute to up to 2% of all non-syndromic cleft lip with or without cleft palate 
cases22. In Msx1-deficient mice, the bilateral primordial palatal shelves form and 
elevate normally, but fail to make contact and never fuse, which results in a cleft 
palate3. Similarly in humans, mutations in or loss of the Msx1 gene result in non-
syndromic clefts of the secondary palate. The homeodomain of Msx1 is crucial in 
mediating several functions, including DNA binding, protein-protein interactions, 
protein stability, and transcription repression23.  
 
2.2.2.1.2. Transforming growth factor-β3 
 TGF-β signaling plays a pivotal role in regulating palatogenesis. During 
mouse palatal development, TGF-β3 is expressed in the medial edge epithelium of 





midline epithelial seam, the expression of TGF-β3 is lost, suggesting crucial 
functions of TGF-β signaling in regulating palatal fusion. Mutations in TGF-β3 
results in 100% penetrance of cleft secondary palate16. The development of cleft 
palate in TGF-β3-null mutant mice is apparently due to a failure of fusion of palatal 
shelves24.  
 
2.2.2.1.3. T-box transcription factor-22 gene 
 Cleft palate with X-linked inheritance has been considered a rare form of 
cleft palate and is characterized by isolated cleft palate and ankyloglossia25. Recent 
studies by Marçano et al. have found that mutations in TBX22 may cause X-linked 
cleft palate. TBX22 encodes a T box containing transcription factor that is expressed 
primarily in the palatal shelves and tongue during palatogenesis, indicating a 
specific role of TBX22 in both palatal and tongue development26.  
 
2.2.2.1.4. Poliovirus receptor like-1 
 PVRL1 was shown to have a significant association with non-syndromic 
cleft lip with or without cleft palate27. PVRL1 encodes a cell adhesion molecule 
called nectin-1, which is expressed at the medial edge epithelium of the developing 
palatal shelves and the skin surface epithelium25. Normal PVRL1 function is 









2.2.2.1.5. Interferon regulatory factor-6 
 IRF6 encodes a transcription factor which regulates the expression of 
Interferon-α and Interferon-β following viral infection. The exact role of IRF6 
during development is unknown. However, in the developing mouse embryo, IRF6 
demonstrates high levels of expression in a variety of craniofacial structures, 
including the medial edges of the fusing palatal processes. This expression pattern 
implies an important role during craniofacial development, with some suggestion 




 PTCH is the human homolog of the Drosophila segment polarity gene 
patched; it encodes a 12-unit transmembrane protein and is the proposed receptor 
for the morphogen sonic hedgehog (SHH). By binding SHH, PTCH transduces a 
repressing signal through smoothened in a downstream pathway to the nucleus. 
Loss of SHH signaling in the chick embryonic face causes defects similar to cleft 
lip and palate in humans. Mutations in PTCH are associated with a variety of birth 
defects and are implicated in the development of nevoid basal cell carcinoma 








2.2.2.2. Syndromes   
It is estimated that 300 syndromes include some form of cleft palate in their 
presentation and a syndrome is diagnosed in one third to one half of isolated cleft 
palate patients19. Van der Woude syndrome is the most common form of syndromic 
cleft lip with or without cleft palate and accounts for about 2% of all of these cases. 
This syndrome is characterized by cleft lip with or without cleft palate, pits or 
mucous cysts on the lower lip, and hypodontia. Van der Woude syndrome is caused 
by a mutation on the IRF6 gene25.  
 Treacher Collins syndrome is dominantly inherited. The principle features 
are underdeveloped facial bones, cleft palate, and conductive hearing loss. Treacher 
Collins syndrome is caused by mutations in the TCOF1 gene13. Stickler syndrome is 
an autosomal dominant disorder of collagen connective tissue associated with 
ocular, auditory, articular, and craniofacial manifestations. Approximately 25% of 
those individuals with Stickler syndrome exhibit some form of midline clefting, 
including cleft palate9.  
 Deletions at 22q11 cause DiGeorge syndrome, and cleft palate occurs in 
about 14% of people with this deletion. Another cause of cleft lip with or without 
cleft palate includes Opitz syndrome, which is caused by mutations in the MID1 
gene, and ectrodactyly, ectodermal dysplasia and cleft lip with or without cleft 








2.2.2.3. Environmental factors 
 Epidemiological studies on different populations have demonstrated links 
between several environmental factors active during pregnancy and a higher risk of 
having a child with a cleft. Some of these include heavy alcohol consumption, 
cigarette smoking, consumption of pharmaceuticals such as anticonvulsants, and 
accidental intake of pesticides30, 31. There has also been recent, preliminary data 
provided which suggests that early embryonic exposure to the cholesterol-lowering 
statin drugs may confer a risk for a wide range of birth defects, including cleft 
palate32. Many teratogens including steroids, ethanol, 13-cis retinoic acid, and 
ionizing radiation along with periods of hypoxia and hypothermia have been shown 
to cause clefting in animal models. Infections, such as rubella and toxoplasmosis 
during the first trimester, have also been associated with clefting4.  
For several years, it has recommended that pregnant women and those 
women planning on having a baby should take folic acid as a daily dietary 
supplement. Several studies have been completed to determine whether maternal 
consumption of folic acid reduces the risk for orofacial clefting in their children. 
These studies have produced mixed results on the effect of folic acid and the 
occurrence of clefts. However, several studies have proven a protective effect of 
maternal multivitamins containing folic acid on the incidence of clefts33, 34.  
Higher risk of orofacial clefts has also been associated with maternal obesity 
and diabetes mellitus. According to one study, the pregnancies of women who were 
both obese and diabetic were 3.1 times more likely to result in an offspring with a 





obesity and diabetes mellitus may act together to increase the risk of congenital 
anomalies, including cleft palate35.  
 
2.3. Current treatments for cleft palate 
 The goals of cleft lip and palate surgery are directed toward achieving a 
normal facial appearance, as well as the ability to feed, speak, and hear without 
significantly affecting the ultimate facial and psychosocial development of the 
child. Cleft lip repair typically occurs at three months of age with palate surgery 
normally performed when a child is between the ages of nine and 18 months.  This 
correlates with speech development and lessens the likelihood of interfering with 
ultimate facial growth4. According to a study performed by Weinfeld et al, single-
staged cleft palate repair is used in 97% of cases36.  Multiple surgical techniques are 
used worldwide, all with relative advantages and disadvantages.  The most common 
palatoplasty techniques being used currently are the von Langenbeck technique37, 
the Bardach two-flap palatoplasty38, the Veau-Wardill-Kilner closure4, 39, the 
Schweckendiek technique, and the Furlow palatoplasty40.  
 In brief, the nasal side closure for most techniques involves the creation of a 
septal flap combined with a lateral nasal flap sutured to one another to create the 
nasal floor. For purposes of palatal closure, the von Langenbeck technique involves 
medial mobilization of full thickness bipedicled hard palate flaps with palatal 
alveolar crest releasing incisions37. The Bardach two-flap palatoplasty uses two 
large full-thickness hard palate flaps that are mobilized and closed anteriorly and 





the three-flap/V-Y technique, is used to increase palatal length to improve function 
by means of a pushback maneuver4, 39. A substantial portion of the hard palate is left 
exposed to heal by secondary intention. The Schweckendiek method is a two-staged 
procedure. The soft palate is first repaired when the patient is three or four months 
old at the time of lip repair. The hard palate is then closed when the patient is about 
18 months old. The Furlow technique is a double opposing Z-plasty procedure for 
the soft palate only. The purpose of the Furlow technique is to reorient the muscle 
of the palate into a functional transverse direction. For hard palate clefts, it is 
usually combined with the von Langenbeck technique. While this method is 
difficult to perform in wide clefts, it may have more utility when the cleft is narrow 
or if a submucous cleft exists36.  
 No benefit has been convincingly demonstrated with any particular repair 
technique when one looks at dental arch form, speech outcome, feeding, or any 
other functional variable. At this point in our understanding, surgeons often 
consider their own experiences and training when repairing clefts, since definitive 
data suggesting that one repair is preferable over another are lacking. 
 
2.3.1. Grafts for hard palate repair 
Alveolar defects create serious disruption of the dentition and collapse of the 
alveolar segments, and are found in 75 percent of cleft patients41.  Bony 
reconstruction of the maxillary-alveolar defect improves facial appearance and 
dental function.  This surgical procedure decreases the need for removable 





eliminating the nasolabial fistula.  Additionally, it establishes a bony environment 
to allow eruption of the permanent cleft-adjacent dentition with subsequent 
orthodontic, fixed prosthetic, or implant based habilitation of the cleft dental gap.  
Other advantages of alveolar bone grafting include provision of bone to support the 
upper lip as well as the cartilaginous skeleton and soft tissues of the nose resulting 
in a global improvement in facial symmetry and aesthetics42.  
 
2.3.1.1. Types of bone grafts 
Bone grafting is categorized as primary, secondary, or tertiary based on the 
timing of the procedure. Primary bone grafting is performed during infancy, at the 
same time as the primary lip or palate repair. Secondary bone grafting is generally 
performed at the end of the mixed dentition driven by the patients’ dental 
development.  It is performed at the developmental stage when either the permanent 
cleft-adjacent lateral incisor or canine is near eruption.   So-called tertiary grafting 
or late secondary grafting is performed following the eruption of the permanent 
canine tooth43.  
 Primary bone grafting was used mainly in the 1950s and 1960s. The main 
objectives in primary bone grafting are elimination of bone deficiency, stabilization 
of the premaxilla to resist scar contracture from the lip and palate repair, creation of 
new bone matrix for eruption of the deciduous teeth in the cleft area, and 
augmentation of the alar base.  There are also expectations of normalization and 





primary bone grafting causes significant growth disturbances of the middle third of 
the facial skeleton, and this procedure has been widely abandoned45.  
 Secondary bone grafting, introduced in 1972 by Boyne and Sands46, 
represents the mainstay of treatment in the habilitation of the alveolar cleft 
deformity. Secondary grafting is performed any time after the primary lip and palate 
repair and can be divided into early (two to five years of age), intermediate (six to 
11 years of age), and late (after eruption of the permanent canine)42.  Early 
secondary grafting, however, results in midface growth restriction similar to that 
seen in cases of primary bone grafting. For this reason, it has little utility on the 
management of the cleft alveolus.  Intermediate secondary bone grafting is 
performed with the intentions of allowing tooth eruption through the grafted bone, 
stabilizing the dental maxillary arch, supporting the nasal soft tissue and cartilage, 
and improving the periodontal health of the dentition.   
The purpose of late grafting is to optimize conditions for prosthetic dental 
treatment such as crowns, bridges, and implants47. Late secondary and tertiary bone 
grafts are performed to enable prosthodontic and periodontal rehabilitation and to 
assist in the closure of persistent bucconasal fistulae. However, this type of graft 
cannot repair bone loss to teeth adjacent to the cleft45, 47.  
Another technique to be considered is the gingivoperiosteoplasty (GPP). 
This technique attempts to avoid the need for future bone grafting by repairing the 
soft tissue component of the alveolar cleft at a very young age. Approximation of 
the gingival and periosteal tissues across the cleft usually takes place at the time of 





osteogenic potential of the infant’s periosteum, such that bone will grow de novo at 
the site of the repaired cleft. If successful, the GPP obviates the need for an 
additional surgical procedure and donor site morbidity. Outcome data regarding the 
effect of this procedure on the subsequent growth of the maxillofacial skeleton are 
insufficient at present to either advocate for its widespread use or complete 
abandonment. 
 
2.3.1.2. Source of bone grafts 
Various donor sites for harvesting bone grafts have been used. Autologous 
cancellous bone from the iliac crest is most often utilized, but may also be harvested 
from the tibia and the mandiblar symphysis. Bone from the cranial vault and rib 
have also been used, but has been shown by some to not perform as well as iliac 
and tibial bone47.  Autologous grafts are advantageous because the entire cleft can 
be filled with viable bone and teeth that erupt through grafted bone respond well to 
orthodontic or orthopedic forces and to maxillary growth.  The adjacent teeth 
around the former cleft have sufficient bony support, adequate closing of the 
oronasal fistulae is facilitated, and reliable support is added to the nasal 
framework48, 49.  
Success of an autologous bone graft depends on the ability of the graft to 
become revascularized.  Cancellous bone is particularly advantageous because it is 
quickly revascularized due to its trabecular nature49.  Additionally, a small number 
of transplanted cells survive providing a stimulus for osteogenic precursor cell 





Cortical bone is another option for cleft grafting. While this type of bone provides 
initial form and strength for reconstruction, it lacks cellularity and revascularization 
is slow because of its compact structure with fewer surface openings, resulting in a 
lengthy transformation and weaker implant49.  
Disadvantages to autologous bone grafts include donor site pain and 
morbidity, a varied rate of success, and the limited volume of bone that is available 
at the donor site51. Moreover, there is blood loss at both the harvest site and the 
implantation site. Other donor site complications include wound dehiscence, 
hematoma, seroma, and paraesthesia. 
 Allogenic bone grafts have been utilized for repair of alveolar clefts52. These 
types of grafts reduce morbidity by eliminating the need for a second surgical site. 
Allogenic bone banks have been established, which make demineralized and freeze-
dried cortical and cancellous bone available for immediate use “off the shelf.”  This 
bone has undergone extensive screening and processing to diminish the risk of 
disease transmission, reduce immunogenicity, and host rejection.  Nevertheless, 
allogenic banked bone has disadvantages as well, which include eliciting a localized 
cellular immunologic reaction and retarding revascularization and osteoinduction. 
There may also be delayed incorporation at the recipient site and increased risk of 
dehiscence and sequestration49.  
 Bone graft substitutes, referred to as alloplasts, have also been considered in 
cleft grafting. These materials, including β-tricalcium phosphate and 
hydroxylapatite, are not recommended in growing patients with unerupted teeth 





found when hydroxylapatite was placed at a surgically created cleft site in an 
animal model by El-Deeb and Horswell54.  Alloplasts, however, have been used for 
alveolar ridge contour augmentation in the adult patient where placement of 
endosteal implants is not anticipated53, 55.  
 
2.4. Limitations to current treatments 
Several complications have been associated with the repair of cleft palate 
deformities.  While these complications can often be minimized by meticulous 
technique and attention to detail, patients are often subjected to multiple revision 
surgeries over their lifetime. In a 1999 study of 374 patients with clefts completed 
by Mackay et al, it was found that patients underwent an average of 3.3 
reconstructive procedures and 1.2 otolaryngologic procedures11. Cohen et al 
evaluated 67 patients aged 14 years or older with cleft lip and palate, finding that 
(1) patients with unilateral cleft lip and palate required an average of 6.12 
procedures and, (2) patients with bilateral cleft lip and palate required an average of 
8.04 additional procedures10.  
 The most obvious complications resulting from palatoplasties include 
wound dehiscence resulting in persistent oral-nasal fistulae as well as scarred and 
immobile palates resulting in hypernasal speech and midface growth restriction. 
Scarring could be caused by the poor handling of the tissues, wound closure under 






Factors which contribute to dehiscence and fistula formation include the 
extent of clefting, errors in technique that include inadequate mobilization of the 
palatal flaps and closure of the incisions under tension, as well as patient and parent 
compliance with postoperative wound care and dietary instructions.  Maxillary-
alveolar (primary palate) fistulae, on the other hand, may be intentionally left to be 
repaired in the mixed dentition to minimized further growth retardation.  Fistulae 
may simply present as asymptomatic conduits or may contribute to velopharyngeal 
incompetence, difficulties with oral hygiene, and nasal regurgitation of liquids and 
food. 
 Disturbances of facial growth are often the result of cleft palate surgery. 
Transverse maxillary hypoplasia and the resulting cross bite are common 
abnormalities in clefts and need to be managed by orthodontic maxillary expansion 
with fixed appliances.  Once expansion is complete, bone grafting is performed to 
consolidate the dental arch correlated with the stage of canine development and 
closely coordinated with planned orthodontic therapy4.  Midface retrusion is another 
common sequela of cleft palate repair.  This results in class III skeletal and dental 
malocclusion.  Orthognathic surgery in conjunction with orthodontic therapy is 
performed the time of skeletal maturity to establish a normal occlusion and 
improved facial form. 
Donor site (tibia, mandible, ilium, cranium, rib) morbidity following bone 
graft harvest is still a recognized limitation in the reconstruction of the cleft primary 
palate.  As with any grafting procedure, complications can be expected in rare 





as in other grafting procedures and include pain, wound infection, bleeding, 
paresthesia, local tissue injury, poor mobility, and fracture of the donor bone.  Late 
complications at the donor site include chronic pain, unaesthetic scarring, gait 
disturbance, and paresthesia.  Growth disturbance has not been reported in the 
pediatric grafting population despite the immaturity of the ilium at the time of 
harvest. 
Despite the widely reported successes and low complication rates of 
multiple bone donor sites utilized in the habilitation of cleft patients, the ideal 
method of reconstruction has not yet been realized. The number of complications 
associated with cleft palate repair is large. While these surgeries aim to restore 
proper function of the palate and provide the patient with normal aesthetics, these 
goals are sometimes not fulfilled. Therefore, other strategies may need to be 
employed to overcome the limitations associated with some surgical techniques.  
 
2.5. Tissue Engineering Strategies for Cleft Palate 
 Tissue engineering strategies promise to deliver improvements in the way 
that bone defects, such as cleft palate, are repaired. Autologous bone is presently 
the preferred material for secondary and tertiary grafting procedures to repair a cleft 
palate. Grafts of this type provide a scaffold on which bone cells can proliferate, 
induce proliferation of undifferentiated cells and their differentiation into 
osteoblasts, and provide a reservoir of skeletal stem and progenitor cells that can 





procedures can induce donor site pain and morbidity, and can lead to anatomical 
and structural complications58.  
 The field of tissue engineering aims to restore function to or replace 
damaged or diseased tissues through the application of engineering and biological 
principles59. These principles include the selection and manipulation of cells, design 
of scaffold matrices, and identification and use of pertinent biological signaling 
molecules. The intended outcome of an implanted tissue engineered construct is a 
new tissue that is structurally and functionally integrated into the surrounding host 
tissue59. Grafting of the hard palate has been abandoned because it has been 
demonstrated that this impedes the maxillary growth in the cleft patient. Therefore, 
we propose a tissue engineering approach for the grafting of the alveolus and/or soft 
tissues in the palate. 
 The following sections provide a basic explanation of the scaffolds, cells, 
and signaling molecules that have been studied for their role in bone tissue 
engineering. These general principles are then further explored as they specifically 
relate to tissue engineering strategies for the repair of cleft palate. Specifically, 
tissue engineering applications for the repair of alveolar clefts and soft tissue 
augmentation are discussed. 
 
2.5.1. Scaffolds 
 The scaffold provides a solid framework for cell growth and differentiation 
at a local site, allowing cell attachment and migration. The scaffold may be 





regeneration, or it may serve as a carrier for cells for the purpose of cell 
replacement therapy60. Scaffolds for engineering bone should be biocompatible, be 
absorbable with rates of resorption comparable to rate of formation of new bone, 
provide a platform on which bone cells can proliferate, have sufficient mechanical 
stability, and be easy to manufacture, sterilize, and handle in the operating room57. 
The scaffold should also have sufficient porosity to accommodate osteoblasts or 
osteoprogenitor cells, to support cell proliferation and differentiation, and to 
enhance bone tissue formation. High interconnectivities between pores are also 
desirable for uniform cell seeding and distribution and the diffusion of nutrients to 
and metabolites out from the cell/scaffold constructs61.  
 Naturally derived or synthetic polymers are commonly used materials for 
bone tissue engineering scaffolds. Polymers have great design flexibility because 
the composition and structure can be tailored to specific needs61. Natural polymers 
are derived from plant or animal sources and are biocompatible, biodegradable, and 
substrates onto which cells can adhere and proliferate. Collagen, chitosan, and 
hyaluronic acid are some natural polymers that have been employed in bone tissue 
engineering applications62-64. Synthetic polymers that have been used in bone tissue 
engineering applications include poly(lactic acid), poly(glycolic acid), and 
poly(lactic-co-glycolic acid). Scaffolds for bone formation may contain inorganic 
compounds to enhance proliferation. Examples include hydroxylapatite, calcium 
phosphate cements, metals and calcium sulfate60.  
 Scaffolds may be in a variety of forms including porous solid meshes, 





can be used to fill irregularly shaped defects, can be administered in a noninvasive 
manner, and can easily incorporate therapeutic agents or cells by simple mixing65.  
 Surface properties of the scaffold, both chemical and topographical, can 
control and affect cellular adhesion and proliferation66. When a scaffold surface 
does not favor cell-matrix interactions, various cell-binding peptides can be 
anchored to the surface of the scaffold to induce cell adhesion and migration. These 
peptides mimic and induce cell-extracellular matrix protein interactions to the 
biomaterial surface through physical or chemical modification methods57. A 
commonly used peptide is the arginine-glycine-aspartic acid (RGD) sequence of 
amino acids67.  
 
2.5.2. Cells 
 The characteristics of an optimal cell source include no immunorejection, no 
graft-versus-host disease, no tumorigenicity, immediate availability, availability in 
large quantities, controlled cell proliferation rate, predictable and consistent 
osteogenic potential, and controlled integration into the surrounding tissues57.  
Autologous bone marrow is a source of mesenchymal stem cells that has 
these characteristics. The isolation of mesenchymal stem cells is easy as it relies 
primarily on the ability of these cells to adhere to tissue-culture plastic, they have a 
high proliferative potential, their default pathway of differentiation is into 
osteoblastic cells, and bone formation is not correlated to the number of cell 





stem cells are thought to be recruited in the body for repair of injured tissues, and 
therefore are good candidates for cell-based tissue engineering therapies70.  
Embryonic stem cells are another source of cells that may be used in tissue 
engineering. These cells exhibit perpetual proliferation in vitro and the ability to 
differentiate into any cell type in the human body60. However, embryonic stem cells 
are a rare resource and for the foreseeable future will remain embroiled in ethical 
and political debates71.  
 
2.5.3. Signaling molecules 
 Often, tissue regeneration requires or is enhanced by the introduction of 
biochemical signals, in the form of growth factors, cytokines, or genes which direct 
cellular responses including proliferation, differentiation, and matrix synthesis60. 
These signals may lead to promotion or prevention of cell adhesion, proliferation, 
migration, and differentiation by up- or down-regulating the synthesis of proteins, 
other growth factors, and/or receptors66.  
 Bone morphogenetic proteins (BMPs) are categorized as a part of the 
transforming growth factor β (TGF-β) superfamily because they are similar in 
protein structure and sequence homology with TGF-β. While their main role is to 
recruit mesenchymal stem cells to the healing site, and then differentiate them into 
the osteogenic lineage, bone morphogenetic proteins also direct the progression of 
cells and their organizational format to tissues and organs in the embryo, influence 
body patterning, limb development, size and number of bones, and modulate post-





considered to be the most osteoconductive of the bone morphogenetic proteins66. 
BMP-2, specifically, promotes undifferentiated mesenchymal cells into osteoblasts, 
leading to bone formation. 
 Other signaling molecules include TGF-β, insulin-like growth factor (IGF), 
vascular endothelial growth factor (VEGF), fibroblast growth factors (FGF), and 
platelet derived growth factor (PDGF)66. TGF-β has been shown to stimulate 
cellular proliferation in vitro and to promote cellular differentiation. IGF genes are 
expressed by skeletal cells and have been found to stimulate type I collage synthesis 
and increase matrix apposition rate73. VEGF is commonly found in bone fracture 
healing sites and the plate growth, and regulates vascularization through the 
recruitment of endothelial cells to the healing sites74. FGF-2 is involved in the bone 
remodeling process. It is believed that it is involved in the regulation of the 
maintenance of the delicate balance between bone forming cells and bone resorbing 
cells and it promotes the development of new blood vessels. PDGF is produced by 
osteoblasts, platelets, monocytes, and macrophages, and is believed to have a role in 
the migration of mesenchymal stem cells to the wound healing site66.  
 
2.5.4. Alveolar bone engineering 
 Secondary bone grafting is routinely practiced as the alveolar cleft treatment 
in patients with cleft lip and cleft palate. However, harvesting a sufficient amount of 
bone is often difficult, and the procedure imposes a heavy burden on the patient. 
Tissue engineering strategies could be employed to lessen these implications. 





 A study by Shimakura and colleagues examined the possibility of achieving 
an autologous transplantation using cryopreserved human bone marrow cells75.  
Xiao et al used human osteoblasts that were isolated from alveolar bone and human 
gingival fibroblasts that were obtained from gingival tissue for bone regeneration76.  
 The three-dimensional structures used today as scaffolds for cells include 
collagen matrices, synthetic organic polymers, and porous forms of hydroxyapatite. 
Hydroxyapatite is highly biocompatible and serves as the scaffold for the 
osteogenic precursor cells, promoting their differentiation into osteoblasts. From an 
examination of bone formation using porous hydroxyapatite with different pore 
sizes, Tsuruga et al concluded that hydroxyapatite with a pore size of 300 to 400 µm 
is best suited for the differentiation of osteoblasts and ingrowth of blood vessels77. 
Hydroxyapatite has also been combined with collagen for use as a bone-equivalent 
composite that can be used for the filling of irregular defects in maxillo-facial 
surgery78. Collagen type I matrices have been seeded with cells and implanted into 
sites where osseous damage has occurred76. Synthetic copolymers, such as poly-L-
lactic acid/polyglycolic acid, have served as an osteoconductive material in bony 
defects79, 80.  
 However, there are some disadvantages with these materials. Particulate 
hydroxyapatite lacks shape and cohesive strength; therefore, it tends to be dislodged 
and to migrate under externally applied forces during the healing period78. Most 
synthetic degradable polymers are based upon an ester backbone. These types of 
materials degrade when water is added to the ester linkage of the polymer 





acidic. As the scaffold degrades, the local acidity of the native tissue increases, and 
this leads to an increase inflammatory response, and further premature degradation 
of the scaffold81, 82.    
Signaling molecules in the bone morphogenetic protein (BMP) family have 
been used to induce cell differentiation into osteoblasts. In 1988, Wozney et al 
sequenced recombinant human BMP-2 (rhBMP-2) and cloned it. Recombinant 
technology now allows production of large, pure quantities of rhBMP-2 that can be 
used clinically and in the laboratory. When placed in the proper environment, 
rhBMP-2 can cause bone formation. Bone forming cells are not necessary to initiate 
this process; rhBMP-2 acts to concentrate host stem cells at the site and then to 
influence their differentiation into bone forming cells. To achieve this effect, 
administration of super-physiologic doses is needed83.  
Chin and colleagues investigated the use of rhBMP-2 as a substitute for 
autologous iliac crest bone for repair of congenital facial clefts in humans. In this 
study, 49 of the 50 alveolar and facial clefts that were repaired had successful 
consolidation demonstrated by radiographs. These radiographs showed no evidence 
of root resorption in any patient and there was ossification across the alveolar cleft 
site only. No case exhibited bone formation outside of the site prepared for 
construction. There was no sign of adverse affects of the rhBMP-2 in any patient or 
on adjacent tissue83. Several other research groups have also used rhBMP-2 with 
positive results in terms of bone augmentation, some specifically for cleft palate 






2.5.5. Soft tissue engineering 
 Although the underlying bone determines to the position of the soft tissue, in 
some cases, the soft tissue may be too thin, of poor vascularity, or of poor quality. 
In these cases, soft tissue augmentation may be required87. Oral reconstructions for 
cleft palate repair are often complicated by a shortage of mucosal tissue. Generally, 
no autologous grafts are used in cleft palate repair; therefore a tissue engineering 
approach could be employed to develop a substitute which could be used to limit 
the iatrogenic effects of cleft palate surgery.  
 Several techniques for the reconstruction of mucosa have been developed 
using keratinocytes cultured on a dermal substrate. Keratinocytes could be obtained 
from both the skin and palatal mucosa. Some researchers believe that the ideal 
mucosal graft should be constructed of autologous oral keratinocytes, grown in a 
serum-free or defined medium without a xenogeneic feeder layer88. A study by 
Ophof et al showed that canine oral keratinocytes cultured on a skin-derived 
substrate at the air-liquid interface form an approximately ten cell layers thick 
parakeratinized epithelium closely resembling normal palatal epithelium of the 
beagle dog89.  
The most widely used types of dermal substrates are skin-derived or 
collagen-based materials. Skin-derived materials are prepared from cadaveric donor 
skin. Human oral keratinocytes have been successfully grown on a decullularized 
human allograft skin90, 91. Type I collagen, sometimes supplemented with 
extracellular matrix components such as collagen type-IV, elastin, or 






2.6. Tissue engineering in children 
 Cleft lip with or without cleft palate is the most prevalent congenital 
craniofacial birth defect in humans and as such, cleft palate is primarily present in 
children. There are several considerations that must be taken into account when 
performing tissue engineering for eventual use in children. 
 Children have been shown to have a better reparative potential than adults 
perhaps due to the increased proliferative capacity of younger cells. For example, it 
has been widely observed that young children and juvenile animals are capable of 
re-ossifying large calvarial defects, while adult animals lack this endogenous tissue 
engineering capacity92, 93. It has also been demonstrated that juvenile osteoblasts 
derived from 2-day-old rats have significantly greater ability to proliferate and form 
bone nodules in vitro compared with adult osteoblasts derived from 60-day-old 
rats94. A study by Haynesworth et al proved that the number of mesenchymal stem 
cells produced in humans decreases as the donor age increases95. The ratio of stem 
cells is 1:10,000 bone marrow cells in newborns, 1:100,000 bone marrow cells in 
teenagers, 1:400,000 cells in persons in their fifties, and 1:2,000,000 cells in 
persons in their eighties96.  Furthermore, another study demonstrated that bone 
marrow stromal cells obtained from elderly donors exhibited decreased proliferation 
potential and accelerated senescence compared with cells obtained from younger 
donors97. Similar results, showing an inverse relationship between donor age and 






 One significant limitation to tissue engineering in children is that the 
engineered construct must be able to account for ongoing growth in the child and 
the distortions that take place in the body following reconstruction. In a study by 
Farkas et. al., normal growth of the nasolabial features were studied in Caucasians 
aged 1 to 18 years and it was found that fast-growing features, such as the upper lip 
and nose, attained more than two-thirds of adult size by the age of five years100, 101.  
Prosthetic materials currently in use do not accommodate dynamic craniofacial 
development and therefore must be repeatedly replaced in pediatric patients as they 
grow102.  The ideal tissue engineered construct will need to be designed to 
encourage unimpeded growth as well as hard and soft tissue healing in the short 
term, allowing its resorption and replacement by the body to occur with minimal 
scarring and local distortion.  
 Another consideration with tissue engineering in children is the limitation in 
donor size. Bone marrow contains mesenchymal stem cells that are able to 
differentiate into several cell lineages, including osteoblastic cells. It is generally 
acceptable to obtain 1-5 milliliters of bone marrow per kilogram of patient 
weight102, 103. As children obviously weigh much less than adults, the amount of 
bone marrow available for harvest from children is limited. To overcome this, a 
much greater amplification of stem cells would be required to avoid the use of 










Chapter 3: A Cyclic Acetal Biomaterial for Tissue Engineering 
 
3.1. Introduction 
Anatomical defects resulting from cleft palate are treated in several ways. 
These include a variety of surgical procedures and bone grafting of the alveolus. 
However, there are several disadvantages of surgical cleft palate repair including 
disturbances of facial growth, scarring, and mandible retrusion. Complications 
associated with bone grafting include donor site pain and morbidity, local tissue 
injury and fracture of the donor bone. In order to overcome these disadvantages, a 
tissue engineering strategy may be used in the repair of cleft palate. Specifically, we 
are investigating strategies for regenerating the alveolar bone that is often missing 
as a result of cleft palate. Tissue engineering combines cells, signaling molecules, 
and biomaterial scaffolds into a construct that is structurally and functionally 
integrated into the surrounding host tissue. The work presented in this thesis focuses 
on developing a biomaterial for use a tissue engineering scaffold.  
 Several materials have already been studied for their role as a bone tissue 
engineering scaffold. These materials fall into the categories of ceramics, natural 
polymers, and synthetic polymers57. Ceramic materials include hydroxyapatite and 
hydroxyapatite-tricalcium phosphate, natural polymers include collagen and 
alginate, and synthetic polymers include polylactic acid, polyglycolic acid, and 
polycaprolactone104. However, there are disadvantages to all of these materials. 





dislodged from the implant site78. Natural polymers, such as collagen, have been 
reported to have mechanical properties significantly less than normal values105. 
Most synthetic degradable polymers are based upon an ester backbone. These types 
of materials degrade when water is added to the ester linkage of the polymer 
backbone. The disadvantage of these materials is that their degradation products are 
acidic. As the scaffold degrades, the local acidity of the native tissue increases, and 
this leads to an increased inflammatory response, and further premature degradation 
of the scaffold81, 82. 
 To overcome this issue, a novel class of biomaterials has been created. 
These novel materials are based upon a hydrolytically degradable cyclic acetal unit. 
These biomaterials degrade by hydrolysis of the cyclic acetal groups, forming diol 
and aldehyde degradation products. These types of compounds will not significantly 
affect the local acidity of the native tissues. Specifically, the material that has been 
examined in the study is 5-ethyl-5-(hydroxymethyl)-β,β-dimethyl-1,3-dioxane-2-
ethanol diacrylate (EHD), which contains a cyclic acetal unit (Figure 3a). These 
monomers, when reacted with the initiator benzoyl peroxide (BP) crosslink to form 
a rigid plastic material (Figures 3b and 3c). BP is a polymerization initiator 
commonly used with acrylates because of its ability to form free radicals. The 





















Figure 3. (a) Chemical structure of 5-ethyl-5-(hydroxymethyl)-β,β-dimethyl-1,3-




































These novel biomaterials can be used in one of two ways. They can be 
prefabricated in vitro, seeded with cells, and then implanted into a bone defect in 
the cleft palate patient. The polymer could also be designed to be an injectable 
biomaterial, which is introduced to the bone defect as a liquid, and then cured in 
vivo to form a solid material. We propose that the optimal method of use for the 
EHD networks is for them to be utilized as injectable materials. 
Therefore, this study was designed to determine the effects of the EHD 
network formulation scheme on several properties of the networks. Specifically, the 
initiator content, volume of diluent, and amount of accelerator were varied 
according to a factorial design. The effect of these parameters on the EHD network 
gelation time, maximum reaction temperature, sol fraction, degree of swelling, and 
cell viability properties were measured and evaluated.  
 
3.2. Materials and Methods 
3.2.1. Materials 
Benzoyl peroxide (BP), N,N-dimethyl-p-toluidine (DMT), 5-ethyl-5-
(hydroxymethyl)-β,β-dimethyl-1,3-dioxane-2-ethanol diacrylate (EHD) were used 
as received from Sigma-Aldrich (Milwaukee, WI, USA). Reagent grade acetone 
was used as received from Fisher Scientific (Pittsburgh, PA, USA).  
 
3.2.2. Experimental design 
A three factor factorial design was employed. The three factors investigated 





acetone, and (3) amount of accelerator, N, N-dimethyl-p-toluidine (DMT). BP 
content was examined at two levels, 2 weight percent and 5 weight percent. The 
amount of diluent was studied at two levels, 0.5 mL/g EHD and 1.0 mL/g EHD. 
Finally, the amount of DMT was examined at three levels, 1 µL/g EHD, 4 µL/g 
EHD, and 8 µL/g EHD. Therefore, a 2 x 2 x 3 design with 12 formulations was 
used. Table 1 presents the compositions of all formulations. For the BP and diluent 
contents, 0 represents the low level of the factor and 1 represents the high level of 
the factor. For DMT, 0 represents the lowest level of the factor, 1 represents the 
medium level of the factor, and 2 represents the highest level of the factor. 
 
Table 1. Outline of the three factor 2 x 2 x 3 factorial design. The three factors that were 
investigated were benzoyl peroxide content (wt %), volume of diluent (mL/g EHD), and 
volume of N,N-dimethyl-p-toluidine (µL/g EHD). The first two factors were investigated 
at two levels (0 and 1), while the third factor was investigated at three levels (0, 1, and 2). 








Low (0):  2 Low (0):  0.5 Low (0): 1 
  Medium (1): 4 
 
High (1):  5 High (1): 1 High (2):  8 
Formulation 
Number Initiator Content Diluent Content 
Accelerator 
Content 
1 0 0 0 
2 0 0 1 
3 0 0 2 
4 0 1 0 
5 0 1 1 
6 0 1 2 
7 1 0 0 
8 1 0 1 
9 1 0 2 
10 1 1 0 
11 1 1 1 







3.2.3. EHD network synthesis 
EHD networks were synthesized using two methods, depending on their 
eventual use. For all studies except the cell attachment studies, the networks were 
formed into disks approximately 22 mm in diameter and 4 mm thick. In order to 
make these disks, 1 g of EHD was measured out. The appropriate mass of BP, 
depending on formulation, was dissolved in the proper amount of diluent. This 
solution was added to the EHD and mixed vigorously. The appropriate volume of 
DMT was added to the EHD solution and mixed well. The solution was then poured 
into a cylindrical glass vial (25 mm in diameter), where it gelled. 
For the cell viability studies, a flat sheet of the EHD networks were made. In 
order to make these sheets, 8 g of EHD was measured out. The appropriate mass of 
BP was dissolved in the proper amount of diluent. This solution was added to the 
EHD and mixed well. The appropriate volume of DMT was added to the EHD 
solution and mixed thoroughly. The solution was then poured into a mold 150 mm 
by 75 mm by 0.9 m and sandwiched between two glass plates, where it gelled. Once 
the networks formed, circles approximately 22 mm in diameter were cut out using a 
cork borer. These networks were washed for 10 minutes each in PBS, acetone, and 
PBS on a shaker table at 100 rpm. 
 
3.2.4. Cell Viability 
 Bone marrow was harvested from the femurs and tibias of adult male Wistar 
Hannover GALAS rats (101-125 g). The cells were cultured in α-minimal essential 





Osteoprogenitor cells adhere to the polystyrene. Media is changed every two days, 
and non-adherent cells are washed away, isolating the osteoprogenitor cells. Cells 
were grown until confluent and passaged cells were used in the cell attachment 
studies. 
Confluent flasks were rinsed with 2 mL of phosphate buffered saline (PBS). 
Cells were incubated at 37 ºC for 8 minutes with 2 mL of trypsin to release the cells 
from the flask. The trypsin was then neutralized with 4 mL of αMEM media + 10% 
FBS. The cell solution was then placed in a 50 mL Falcon tube and 100 µL of the 
solution was removed to count the cells, using a hemacytometer. The cells were 
centrifuged for 5 minutes at 1500 rpm. The cell pellet was resuspended in αMEM 
media + 10% FBS. 
Cells were seeded onto the surface of EHD networks at a density of 400,000 
cells / 22 mm diameter disc. Osteoprogenitor cells were cultured with αMEM media 
+ 10% FBS incubated at 37°C at 5% CO2. Osteoprogenitor cells were allowed to 
attach and proliferate in these conditions for 2 days. The cells were then assayed for 
viability using 0.4% trypan blue stain. Both viable and nonviable osteoprogenitor 
cells were counted using a hemacytometer. The cell viability was calculated using 
the formula: 
 
Cell viability =   (Number of alive cells / Total number of cells) x 100%  
         
Each sample was run in triplicate; the reported values are the mean values and the 





   
3.2.5. Gelation time 
The gelation time was determined using a rheometer (Model AR 2000, TA 
Instruments, New Castle, DE) equipped with a 20 mm diameter stainless steel flat 
plate geometry. The gelation point was defined as the time corresponding to the 
formation of an infinite polymer network in which all of the chains are bound 
together at a minimum of one site106.  At the gelation point, the polymer viscosity 
change with time asymptotically approaches infinity. A representative gelation time 










Figure 4. A representative gelation time plot. Gelation time was defined as the x value of 
the intersection between a line drawn through the initial viscosity region, and a line 
drawn through all points where the viscosity is greater than 100 times that of the initial 
viscosity. 
 
The components of each formulation in Table 1 were weighed out, using 0.5 
g EHD as a basis. The corresponding mass of BP was dissolved in the appropriate 






























well. Next, the proper amount of DMT was added to the EHD solution and mixed 
thoroughly. DMT was added at time zero and a stop watch was started at this point. 
The EHD solution was injected into the rheometer with the gap set to 500 µm. A 
time sweep was performed on each of the samples at a frequency of 20 rad/s and a 
constant 10% strain. Each sample type was run five times; the reported values are 
the mean values and the associated errors are the standard deviations. 
 
3.2.6. Temperature profiles 
The temperature of the EHD networks during the gelation time was 
measured using a thermocouple. One gram of EHD was measured out in a 25 mm 
diameter glass vial. The appropriate mass of BP was dissolved in the correct 
amount of diluent and this solution was added to the EHD and mixed well. The 
proper volume of DMT was added to the EHD solution and mixed thoroughly. A 
wire thermocouple (Control Company) was then inserted into the center of the 
sample. The thermocouple was kept away from the bottom and sides of the glass 
vial. Initial temperature of the samples was 23.2 ± 1.3 ºC. Temperature 
measurements were then taken and recorded using a Traceable Data Acquisition 
System (Control Company) once a second until the sample temperature returned to 
within 2 ºC of the initial temperature. The maximum temperature was then 
determined for each sample. A representative temperature profile is shown in 
Figure 5. Each sample type was run five times; the reported values are the mean 






























Figure 5. A representative temperature profile. The maximum reaction temperature for 
each temperature profile was determined. 
  
3.2.7. Sol fraction and degree of swelling 
A study of the EHD network sol fraction was performed using the EHD 
network disks, whose fabrication was described previously. Once the networks had 
gelled, they were patted dry with weigh paper and weighed (Wi). Each sample was 
placed in a vial containing 10 mL of acetone, as EHD monomers are soluble in 
acetone, but the EHD networks are not. The samples were then removed from the 
acetone after 24 h and the surface was patted dry with weigh paper and each sample 
was weighed (Ww). The networks were then placed in vials and were left in a fume 





placed in an oven set at 60 ºC and were periodically weighed until their mass 
stabilized (Wd). The sol fraction was calculated using the formula: 








The degree of swelling was calculated using the formula: 
 








Each sample type was run five times; the reported values are the mean values and 
the associated errors are the standard deviations. 
 
3.2.8. Cell Attachment 
Bone marrow was harvested from the femurs and tibias of adult male Wistar 
Hannover GALAS rats (101-125 g). The cells were cultured in αMEM media + 
10% FBS in a T-75 polystyrene flask. Osteoprogenitor cells adhere to the 
polystyrene. Media is changed every two days, and non-adherent cells are washed 
away, isolating the osteoprogenitor cells. Cells were grown until confluent and 
passaged cells were used in the cell attachment studies. 
 Confluent flasks were rinsed with 2 mL of phosphate buffered saline (PBS). 
Cells were incubated at 37 ºC for 8 minutes with 2 mL of trypsin to release the cells 
from the flask. The trypsin was then neutralized with 4 mL of αMEM media + 10% 





solution was removed to count the cells, using a hemacytometer. The cells were 
centrifuged for 5 minutes at 1500 rpm. The cell pellet was resuspended in αMEM 
media + 10% FBS. 
 Cells were seeded at a density of 150,000 cells/well in a 12 well plate. The 
experimental group was the EHD networks of formulations 1, 4, 7, and 10. The 
EHD networks were prevented from floating by a 16 mm inner diameter stainless 
steel ring. There were two controls: an empty well and a well with the stainless steel 
ring inserts. 
 Cell attachment was determined at 4 hours and 8 hours after initial seeding. 
Each well was rinsed with 0.2 mL of PBS. Cells were incubated at 37 ºC for 8 
minutes with 0.2 mL of trypsin to release the cells. The trypsin was the neutralized 
with 0.4 mL of αMEM media + 10% FBS. Cells were counted using a 
hemacytometer. Both controls at each time point were run ten times and the 
experimental groups at both time points were run five times; the reported values are 
mean values and the associated errors are standard deviations. 
 
3.2.9. Statistics 
The results of the 2 x 2 x 3 factorial design were studied by an analysis of 
variance (ANOVA). Three factors were investigated, and therefore a total of seven 
effects could be identified. These include three main factor effects (the effect of BP, 
the effect of diluent, and the effect of DMT), three two-factor interactions (the 
effect of BP and diluent, the effect of BP and DMT, and the effect of diluent and 





value, F critical value, and p value were calculated for each of the effects. The 
resulting p values are reported. A significance level of 95% (α = 0.05) was chosen, 
therefore an effect with a p value of <0.05 is considered to be significant. While all 




3.3.1. Cell viability 
As a preliminary study, the cell viability on the EHD networks was 
determined as a function of the amount of DMT used in formulating the networks. 
Because DMT is toxic, it was important to determine that the cells would not die 
when allowed to grow on EHD networks that contain DMT. The cell viability on 
the EHD networks containing DMT varied between 87.9% and 89.1% (Figure 10). 
There is no significant difference in the viability between the experimental groups 
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Figure 6. Osteoprogenitor cell viability on EHD networks containing 0.4167, 0.8333, and 
1.6667 µL DMT / g EHD. Results are compared with viability results on a polystyrene 





3.3.2. Gelation time 
 In order to measure the rate of the EHD polymerization reaction, the 
gelation time for each of the EHD network formulations was found. The gelation 
time was determined by monitoring a change in the EHD solution viscosity with 
time.  The time that the networks take to gel decreases from 193.9 s to 33.3 s as the 
volume of initiator, DMT, increases (Figure 6). Analysis of the results from the 
factorial design study showed the main effect of BP, the main effect of diluent, and 
the main effect of DMT to be statistically significant in determining the gelation 
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Figure 7. The effect of BP content, volume of diluent, and volume of DMT on the EHD 
network gelation time. All factors, BP content (p = 2.7 x 10-4), volume of diluent (p = 6.9 
x 10-5), and volume of DMT (p = 3.9 x 10-6) were found to be significant in determining 
the gelation time. 
 
3.3.3. Temperature profiles 
 As the EHD networks could potentially be formed in vivo, it is imperative to 
examine the temperature profiles of the networks as they form. An important piece 
of information obtained from these profiles is the maximum temperature reached by 
the networks as they formed. The maximum reaction temperature increases from 
31.9 ºC to 109.0 ºC as the BP content increased from 2 wt% to 5 wt% and the 
volume of DMT increased from 1 µL/g EHD to 8 µL/g EHD (Figure 7). Analysis of 
the results from the factorial design study showed the main effect of BP, the main 





determining the gelation time. The volume of diluent was found to be the parameter 
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Figure 8. The effect of BP content, volume of diluent, and volume of DMT on the 
maximum temperature reached during EHD network formation. All factors, BP content 
(p = 1.1 x 10-3), volume of diluent (p = 9.6 x 10-11), and volume of DMT (p = 2.4 x 10-10) 
were found to be significant in determining the maximum temperature. 
 
3.3.4. Sol fraction 
 The sol fraction of a material is a measure of the amount of unreacted 
components. A decrease in sol fraction corresponds to a decrease in the amount of 
unreacted material. The sol fraction of the EHD networks decreases from 45.0% to 





decreased from 1 mL/g EHD to 0.5 mL/g EHD (Figure 8). Analysis of the results 
from the factorial design study showed the main effect of BP, the main effect of 
diluent, and the main effect of DMT to be statistically significant in determining the 
sol fraction. The volume of diluent was found to be the parameter that most affects 
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Figure 9. The effect of BP content, volume of diluent, and volume of DMT on the sol 
fraction of the EHD networks. All factors, BP content (p = 3.3 x 10-3), volume of diluent 
(p = 4.2 x 10-14), and volume of DMT (p = 3.4 x 10-2) were found to be significant in 
determining the sol fraction. 
 
3.3.5. Degree of swelling 
 The swelling degree of a material is a measure of its ability to uptake liquid 
molecules and hold them between the polymer chains. The swelling degree of the 
EHD networks increases from 29.9% to 48.3% as the BP content decreases from 5 





EHD, and the volume of DMT increases from 1 µL/g EHD to 8 µL/g EHD (Figure 
9). Analysis of the results from the factorial design study showed the main effect of 
diluent and the main effect of DMT to be statistically significant in determining the 
degree of swelling. The volume of diluent was found to be the parameter that most 
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Figure 10. The effect of BP content, volume of diluent, and volume of DMT on the 
degree of swelling of the EHD networks. The volume of diluent (p = 9.3 x 10-13) and the 
volume of DMT (p = 4.8 x 10-5) were found to be significant in determining the swelling 




3.3.6. Cell Attachment 
 As the EHD networks could be used as prefabricated materials with 
osteoprogenitor cells seeded on the material before implantation, it is important to 





between 7.3% and 78.3% at 4 hours (Figure 11). At this time point, it was 
determined that there was a significant difference in the cell attachment between the 
empty control and all other groups, between the insert control and all other groups, 
between Formulations 1 and 7, between Formulations 1 and 10, between 
Formulations 4 and 7, between Formulations 4 and 10, and between Formulations 7 
and 10. 
At 8 hours, the cell attachment varied between 14% and 77.3% (Figure 11). 
At this time point, it was determined that there was a significant difference in the 
cell attachment between the empty control and the insert control and Formulations 
1, 4, and 7, between the insert control and Formulations 1, 4, and 7, between 
Formulations 1 and 10, between Formulations 4 and 10, and between Formulations 
7 and 10. 
Finally, it was also determined that there was no significant difference in the 
cell attachment between 4 and 8 hours in the empty control group, the insert control 
group, Formulation 1, and Formulation 4. There was a significant difference in the 
cell attachment between the 4 and 8 hour time points for Formulation 7 and 
























Figure 11. Cell attachment properties of osteoprogenitor cells on EHD networks 
fabricated with Formulations 1, 4, 7, and 10. This property was determined at 4 and 8 
hour time points. The results were compared with the cell attachment properties on an 
empty control (tissue culture polystyrene) and an insert control (tissue culture polystyrene 




 We are proposing here the use of the novel cyclic acetal biomaterial EHD as 
a bone tissue scaffold for the repair of cleft palates. The fabrication parameters, 
including the amount of initiator, BP, the amount of diluent, acetone, and the 
amount of accelerator, DMT, used each have an influence on the properties of the 
material. In this study, these components were varied in a factorial design to 
measure their main effects on the gelation time, maximum temperature reached, sol 
fraction, swelling degree, and cell attachment. By examining these properties for 





 As a preliminary study, the viability of osteoprogenitor cells on the EHD 
networks was determined. As we propose using EHD as a biomaterial for bone 
tissue engineering, it is imperative that cells are viable on the material. We found 
that there was no decreased viability of the cells on the EHD networks as compared 
to a control of tissue culture polystyrene.  
  The first goal of this work was to determine the effect that the initiator 
content has on the properties of the novel EHD networks. The amount of initiator, 
here BP, which is present in the reaction system is linked to the rate of the reaction. 
Increasing the amount of initiator should increase the rate of the reaction. The 
gelation time of the EHD networks varied between 33.3 and 193.9 s. According to 
the results of the gelation time experiments, the gelation time could be reduced by 
increasing the BP content. Increasing the amount of BP causes more free radicals to 
form, which in turn makes it easier for the free radical on one EHD molecule to find 
the free radical on another EHD molecule, thus reducing the gelation time. The 
maximum reaction temperature of the EHD polymerization reaction increases from 
31.9 ºC to 109.0 ºC as the BP content increased from 2 wt% to 5 wt%. As the 
amount of BP increases, the EHD networks form faster, and the reaction 
temperature is increased. The sol fraction of the EHD networks showed a minimum 
value for all formulations of 22.0%, with a maximum value of 45.0%.The sol 
fraction generally increases as the BP content decreases. As the BP content 
decreases, fewer free radicals are formed and smaller EHD chains are made, These 
small chains are easily dissolved and washed away, leading to an increase in sol 





48.3%. However, BP was not found to be a determining factor of the EHD network 
swelling degree. 
 Like the initiator content, the amount of accelerator, here DMT, which is 
present in the reaction system is associated to the rate of reaction. Increasing the 
amount of initiator should increase the rate of the reaction. Therefore, another goal 
of this work was to determine the effect that the accelerator content has on the 
physical properties of the fabricated EHD networks. Increasing the accelerator 
content was found to reduce the gelation time of the EHD networks. Increasing the 
amount of DMT causes the polymerization reaction of EHD to be accelerated, thus 
reducing the gelation time. The main effect of DMT was found to be the most 
significant parameter in determining the gel time. The temperature profile 
experiments showed that as the volume of DMT increased, the maximum 
temperature of the reaction also increased. This is because increasing the DMT 
content causes the EHD networks to form faster. In turn, this violent polymerization 
causes the temperature of the reaction to increase. The DMT content was found to 
be a minor determining factor of the EHD network sol fraction. As the volume of 
DMT increases, the sol fraction of the networks was also found to increase. The 
DMT content of the formulation was found to be a significant determinant of the 
swelling degree of the EHD networks. The swelling degree was generally found to 
increase as the volume of DMT increased.  
 A third goal of this work was to determine the effect that the diluent content 
has on the properties of EHD networks. The amount of diluent, here acetone, which 





reaction. Reducing the diluent content causes a decrease in the gelation time of the 
networks. Increasing the amount of diluent increases the distance between EHD 
molecules. This makes it more difficult for the free radical on one EHD molecule to 
find another free radical to react with, thereby increasing the gelation time. The 
maximum reaction temperature was most affected by the diluent content. As the 
volume of diluent decreases, the maximum reaction temperature generally 
increases. From the factorial design, it is apparent that the volume of diluent in the 
formulation is the also the most significant factor in determining the sol fraction. 
Increasing the volume of diluent in the formulation causes the sol fraction to 
decrease. Again, an increase in the amount of diluent causes the EHD monomers to 
be further spread apart, leading to smaller polymerized EHD chains. These smaller 
chains are more easily dissolved in the diluent than larger EHD chains, leading to a 
decrease in the sol fraction. The swelling degree was found to be most significantly 
determined by the volume of diluent in the formulation. As the diluent content is 
increased, the swelling degree of the network is also increased. As previously 
described, increasing the diluent volume causes a separation of EHD monomers, 
leading to an increase in the amount of void space in the network once the residual 
diluent has evaporated. When the networks are then replaced in acetone, the solvent 
easily fills the void spaces, leading to a higher degree of swelling. 
 The final goal of this work was to determine the cell attachment properties 
of the networks. This property was only studied in the formulations containing the 
lowest volume of DMT because we would not want a patient to be subjected to any 





was a significant difference between the cell attachment properties of all 
experimental groups and the empty control, and between all experimental groups 
and the insert control at 4 hours. However, at 8 hours, the attachment on 
Formulation 10 was not significantly different from that of the empty or insert 
controls. As the cells would be seeded on the biomaterial more than 8 hours before 
implantation, these results are promising. Formulation 10 is the most promising 
formulation in regards to the cellular attachment properties. 
 In selecting the most attractive fabrication scheme for the EHD networks, it 
is important to identify the formulation that has the fastest rate of reaction while 
also having the most complete reaction. Therefore, we believe that the most 
desirable EHD network to be used as a biomaterial is one that is formulated with 
either a high or low BP content, a low DMT content, and a high acetone content. 
These combinations lead to networks with a reasonable gelation time, a low 
maximum reaction temperature, a low sol fraction, a low swelling degree, and a 
high degree of cellular attachment. The formulations that fit these requirements are 
formulations 4 and 10. 
 
3.5. Conclusions 
This work investigated the properties of a novel cyclic acetal biomaterial 
that could be used in bone tissue engineering applications, and specifically for the 
regeneration of alveolar bone that is often missing in patients with a cleft palate. 
Monomers of EHD are reacted to form EHD networks. This study was designed to 





of the networks. Specifically, the effects of initiator content and volumes of diluent 
and accelerator on several properties of the EHD networks were examined. The 
results show that the EHD networks can be optimized for a fast gelation time, low 
maximum reaction temperature, low sol fraction, low swelling degree, and 
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